[go: up one dir, main page]

PE20210401A1 - Composiciones farmaceuticas que comprenden meloxicam - Google Patents

Composiciones farmaceuticas que comprenden meloxicam

Info

Publication number
PE20210401A1
PE20210401A1 PE2020002265A PE2020002265A PE20210401A1 PE 20210401 A1 PE20210401 A1 PE 20210401A1 PE 2020002265 A PE2020002265 A PE 2020002265A PE 2020002265 A PE2020002265 A PE 2020002265A PE 20210401 A1 PE20210401 A1 PE 20210401A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
compositions including
meloxicam
including meloxicam
composition
Prior art date
Application number
PE2020002265A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69059998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20210401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of PE20210401A1 publication Critical patent/PE20210401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

En la presente descripcion se describe una composicion que comprende meloxicam, 400 mg de bicarbonato de sodio y un farmaco triptano tal como rizatriptan, donde dicha composicion tambien puede comprender una ciclodextrina. Estas composiciones pueden administrarse por via oral, por ejemplo, para mejorar la biodisponibilidad, la solubilidad o la farmacocinetica del farmaco para el tratamiento de afecciones tales como el dolor
PE2020002265A 2018-07-03 2019-07-03 Composiciones farmaceuticas que comprenden meloxicam PE20210401A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862693871P 2018-07-03 2018-07-03
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
PCT/US2019/040495 WO2020010196A1 (en) 2018-07-03 2019-07-03 Pharmaceutical compositions comprising meloxicam

Publications (1)

Publication Number Publication Date
PE20210401A1 true PE20210401A1 (es) 2021-03-02

Family

ID=69059998

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020002265A PE20210401A1 (es) 2018-07-03 2019-07-03 Composiciones farmaceuticas que comprenden meloxicam

Country Status (18)

Country Link
US (1) US20220096490A1 (es)
EP (1) EP3817722A4 (es)
JP (3) JP7237375B2 (es)
KR (2) KR102815027B1 (es)
CN (1) CN112384198A (es)
AU (3) AU2019297360B2 (es)
BR (1) BR112020026965A2 (es)
CA (1) CA3105476A1 (es)
CL (1) CL2020003443A1 (es)
CO (1) CO2021000789A2 (es)
CR (1) CR20210061A (es)
IL (1) IL279442A (es)
MX (2) MX2020014128A (es)
MY (1) MY199007A (es)
NI (1) NI202000105A (es)
PE (1) PE20210401A1 (es)
SG (1) SG11202012376PA (es)
WO (1) WO2020010196A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12485176B2 (en) 2015-02-10 2025-12-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
EP4132511A4 (en) * 2020-04-06 2024-05-15 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US20240058354A1 (en) 2020-04-06 2024-02-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12128052B2 (en) 2020-05-28 2024-10-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP2024502041A (ja) 2020-12-31 2024-01-17 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含む医薬組成物
US12370196B2 (en) 2020-12-31 2025-07-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12005118B2 (en) * 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348979A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
CA2527368A1 (en) 2003-06-06 2004-12-23 Glaxo Group Limited Pharmaceutical composition
EP3216445A1 (en) 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
ATE502921T1 (de) * 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN101984960B (zh) * 2010-10-29 2011-10-26 四川梓橦宫药业有限公司 苯甲酸利扎曲普坦胶囊及其制备方法
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) * 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102447080B1 (ko) * 2015-11-25 2022-09-23 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
KR20210027371A (ko) 2021-03-10
MY199007A (en) 2023-10-09
JP2024102219A (ja) 2024-07-30
AU2025202015A1 (en) 2025-04-10
WO2020010196A1 (en) 2020-01-09
JP7485807B2 (ja) 2024-05-16
CO2021000789A2 (es) 2021-01-29
JP2023062134A (ja) 2023-05-02
MX2020014128A (es) 2021-06-18
BR112020026965A2 (pt) 2021-03-30
JP2021529759A (ja) 2021-11-04
IL279442A (en) 2021-01-31
CR20210061A (es) 2021-03-18
CN112384198A (zh) 2021-02-19
EP3817722A1 (en) 2021-05-12
KR20250085839A (ko) 2025-06-12
AU2019297360B2 (en) 2022-07-21
KR102815027B1 (ko) 2025-05-30
EP3817722A4 (en) 2022-03-23
CL2020003443A1 (es) 2021-05-07
AU2019297360A1 (en) 2021-01-28
NI202000105A (es) 2021-03-23
SG11202012376PA (en) 2021-01-28
JP7237375B2 (ja) 2023-03-13
NZ771802A (en) 2024-07-26
AU2022252856B2 (en) 2024-12-19
MX2024005716A (es) 2024-05-24
US20220096490A1 (en) 2022-03-31
AU2022252856A1 (en) 2022-11-17
CA3105476A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
EP4467600A3 (en) Pharmaceutical compositions comprising meloxicam
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
BR112022004099A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
MX2018014232A (es) Formulacion farmaceutica.
CO2025007025A2 (es) Formulaciones orales compactables de ibutamoren
PE20061418A1 (es) Composiciones farmaceuticas de 4-[(ciclopropanocarbonilamino)metil]-2-(2,6-dioxopiperidin-3-il)isoindol-1,3-diona para el tratamiento o prevencion de lupus cutaneo
PE20220381A1 (es) Formulacion de tableta vaginal
AR068560A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota artritis gotosa y enfermedades relacionadas
ECSP23005057A (es) Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo
ECSP21006974A (es) Composiciones farmacéuticas que comprenden meloxicam
BR112023003572A2 (pt) Formulação oral sólida de utidelona
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
NZ742220B2 (en) Pharmaceutical compositions comprising meloxicam
CO2021006473A2 (es) Composición farmacéutica que comprende la combinación de un inhibidor selectivo de la ciclooxigenasa 2 y un carbamato derivado de la guaifenesina para el tratamiento del dolor, inflamación y contractura muscular
AR117298A1 (es) Aglutinante de péptido
AR118056A2 (es) Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas
NZ760052A (en) Methods of treatment for cystic fibrosis